{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:43:20Z","timestamp":1788623000649,"version":"build-2803163510"},"reference-count":55,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Metabolic health is tightly regulated by neuro-hormonal control, and systemic metabolic dysfunction may arise from altered function of the hypothalamic\u2013anterior pituitary axis (HAPA). Ancient experimental observations of hypothalamic obesity (HO) and liver cirrhosis occurring among animals subjected to hypothalamic injury can now be explained using the more recent concepts of lipotoxicity and metabolic dysfunction-associated steatotic liver disease (MASLD). Lipotoxicity, the range of abnormalities resulting from the harmful effects of fatty acids accumulated in organs outside of adipose tissue, is the common pathogenic factor underlying closely related conditions like hypothalamic syndrome, HO, and MASLD. The hormonal deficits and the array of metabolic and metabolomic disturbances that occur in cases of HO are discussed, along with the cellular and molecular mechanisms that lead, within the MASLD spectrum, from uncomplicated steatotic liver disease to steatohepatitis and cirrhosis. Emphasis is placed on knowledge gaps and how they can be addressed through novel studies. Future investigations should adopt precision medicine approaches by precisely defining the hormonal imbalances and metabolic dysfunctions involved in each individual patient with HO, thus paving the way for tailored management of MASLD that develops in the context of altered HAPA.<\/jats:p>","DOI":"10.3390\/metabo14080408","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T13:04:59Z","timestamp":1721999099000},"page":"408","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["From Hypothalamic Obesity to Metabolic Dysfunction-Associated Steatotic Liver Disease: Physiology Meets the Clinics via Metabolomics"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-0698","authenticated-orcid":false,"given":"Amedeo","family":"Lonardo","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Azienda Ospedaliero-Universitaria of Modena (-2023), 41126 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-0931","authenticated-orcid":false,"given":"Ralf","family":"Weiskirchen","sequence":"additional","affiliation":[{"name":"Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), Rheinisch-Westf\u00e4lische Technische Hochschule (RWTH), University Hospital Aachen, D-52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rusch, J.A., Layden, B.T., and Dugas, L.R. (2023). Signalling cognition: The gut microbiota and hypothalamic pituitary-adrenal axis. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1130689"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/ceh.2021.104441","article-title":"Non-alcoholic fatty liver disease and lipotoxicity","volume":"7","author":"Wasilewska","year":"2021","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1152\/physrev.1946.26.4.541","article-title":"Mechanism of the development of obesity in animals with hypothalamic lesions","volume":"26","author":"Brobeck","year":"1946","journal-title":"Physiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"10878","DOI":"10.1073\/pnas.91.23.10878","article-title":"Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: Impairment in adipocyte beta-cell relationships","volume":"91","author":"Lee","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/sj.ki.5001834","article-title":"Lipotoxicity","volume":"70","author":"Weinberg","year":"2006","journal-title":"Kidney Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bbalip.2009.12.011","article-title":"Obesity as a clinical and public health problem: Is there a need for a new definition based on lipotoxicity effects?","volume":"1801","author":"Virtue","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/hep.20140","article-title":"Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction","volume":"39","author":"Adams","year":"2004","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2006.03.005","article-title":"\u2018Endocrine NAFLD\u2019 a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis","volume":"44","author":"Lonardo","year":"2006","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nrgastro.2009.33","article-title":"Endocrine and liver interaction: The role of endocrine pathways in NASH","volume":"6","author":"Loria","year":"2009","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11102-008-0096-4","article-title":"Review of physiology, clinical manifestations, and management of hypothalamic obesity in humans","volume":"12","author":"Lee","year":"2009","journal-title":"Pituitary"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dom.15530","article-title":"Acquired hypothalamic obesity: A clinical overview and update","volume":"26","author":"Roth","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000262539","article-title":"Hypothalamic obesity","volume":"17","author":"Hochberg","year":"2010","journal-title":"Endocr. Dev."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Romigi, A., Feola, T., Cappellano, S., De Angelis, M., Pio, G., Caccamo, M., Testa, F., Vitrani, G., Centonze, D., and Colonnese, C. (2022). Sleep Disorders in Patients With Craniopharyngioma: A Physiopathological and Practical Update. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.817257"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lonardo, A., Leoni, S., Alswat, K.A., and Fouad, Y. (2020). History of Nonalcoholic Fatty Liver Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165888"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1055\/s-0028-1091980","article-title":"Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease","volume":"28","author":"Malhi","year":"2008","journal-title":"Semin. Liver Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: Revisited after a decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction associated steatotic liver disease (MASLD): Beyond insulin resistance","volume":"79","author":"Hutchison","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lonardo, A., Mantovani, A., Lugari, S., and Targher, G. (2019). NAFLD in some common endocrine diseases: Prevalence, pathophysiology, and principles of diagnosis and management. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20112841"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jhep.2021.01.045","article-title":"Diagnosis and management of secondary causes of steatohepatitis","volume":"74","author":"Liebe","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/cen.13042","article-title":"Liver fat in adults with GH deficiency: Comparison to matched controls and the effect of GH replacement","volume":"85","author":"Meienberg","year":"2016","journal-title":"Clin. Endocrinol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7154907","DOI":"10.1155\/2022\/7154907","article-title":"Metabolic effects of recombinant human growth hormone replacement therapy on juvenile patients after craniopharyngioma tesection","volume":"2022","author":"Li","year":"2022","journal-title":"Int. J. Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11102-020-01031-5","article-title":"Growth hormone therapy in adults with growth hormone deficiency: A critical assessment of the literature","volume":"23","author":"He","year":"2020","journal-title":"Pituitary"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"294278","DOI":"10.1155\/2015\/294278","article-title":"Sex hormones and their receptors regulate liver energy homeostasis","volume":"2015","author":"Shen","year":"2015","journal-title":"Int. J. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2337\/db11-1718","article-title":"Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance","volume":"62","author":"Zhu","year":"2013","journal-title":"Diabetes"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/bs.apcsb.2019.01.001","article-title":"Estrogen receptor signaling mechanisms","volume":"116","author":"Fuentes","year":"2019","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zhou, Z., Zhang, S., and Hu, F. (2021). Endocrine disorder in patients with craniopharyngioma. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.737743"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.dld.2018.12.014","article-title":"Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?","volume":"51","author":"Lonardo","year":"2019","journal-title":"Dig. Liver Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_30","first-page":"1","article-title":"Leptin and beyond: An odyssey to the central control of body weight","volume":"84","author":"Li","year":"2011","journal-title":"Yale J. Biol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00431-008-0876-x","article-title":"The role of leptin, soluble leptin receptor, resistin, and insulin secretory dynamics in the pathogenesis of hypothalamic obesity in children","volume":"168","author":"Guran","year":"2009","journal-title":"Eur. J. Pediatr."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Cortegana, C., Garc\u00eda-Galey, A., Tami, M., Del Pino, P., Carmona, I., L\u00f3pez, S., Alba, G., and S\u00e1nchez-Margalet, V. (2021). Role of leptin in non-alcoholic fatty liver disease. Biomedicines, 9.","DOI":"10.3390\/biomedicines9070762"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e230365","DOI":"10.1530\/JOE-23-0365","article-title":"Glucagon resistance and metabolic-associated steatotic liver disease: A review of the evidence","volume":"261","author":"McGlone","year":"2024","journal-title":"J. Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., and Sasso, F.C. (2023). GLP-1 receptor agonists in non-alcoholic fatty liver disease: Current evidence and future perspectives. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021703"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1515\/jpem-2017-0350","article-title":"Metabolic features and changes in glucose-induced serum glucagon-like peptide-1 levels in children with hypothalamic obesity","volume":"33","author":"Aroonparkmongkol","year":"2020","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e230462","DOI":"10.1530\/EC-23-0462","article-title":"The distinct hepatic metabolic profile and relation with impaired liver function in congenital isolated growth hormone-deficient rats","volume":"13","author":"Guo","year":"2024","journal-title":"Endocr. Connect."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Chen, P., and Fang, X. (2024). Proteomic and metabolomic analysis of GH deficiency-induced NAFLD in hypopituitarism: Insights into oxidative stress. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1371444"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Zhang, Q., Feng, Y., Wu, D., Xie, Y., Wu, G., Wu, W., Wang, H., Liu, X., Fan, L., and Xiang, B. (2024). Serum metabolomic and lipidomic profiling reveals the signature for postoperative obesity among adult-onset craniopharyngioma. Metabolites, 14.","DOI":"10.3390\/metabo14060338"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"zqad044","DOI":"10.1093\/function\/zqad044","article-title":"Deficiency of phosphatidylethanolamine synthesis: Consequences for skeletal muscle","volume":"4","author":"Duncan","year":"2023","journal-title":"Function"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"25704","DOI":"10.1074\/jbc.M109.023846","article-title":"The development of a metabolic disease phenotype in CTP:phosphoethanolamine cytidylyltransferase-deficient mice","volume":"284","author":"Fullerton","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1113\/EP091545","article-title":"A high-fat diet supplemented with medium-chain triglycerides ameliorates hepatic steatosis by reducing ceramide and diacylglycerol accumulation in mice","volume":"109","author":"Mourad","year":"2024","journal-title":"Exp. Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"101725","DOI":"10.1016\/j.molmet.2023.101725","article-title":"Carboxylesterase 2a deletion provokes hepatic steatosis and insulin resistance in mice involving impaired diacylglycerol and lysophosphatidylcholine catabolism","volume":"72","author":"Chalhoub","year":"2023","journal-title":"Mol. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Preuss, C., Jelenik, T., B\u00f3dis, K., M\u00fcssig, K., Burkart, V., Szendroedi, J., Roden, M., and Markgraf, D.F. (2019). A new targeted lipidomics approach reveals lipid droplets in liver, muscle and heart as a repository for diacylglycerol and ceramide species in non-alcoholic fatty liver. Cells, 8.","DOI":"10.3390\/cells8030277"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S1590-8658(02)80194-3","article-title":"Policentrica Steatosi Epatica Non Alcolica. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study","volume":"34","author":"Lonardo","year":"2002","journal-title":"Dig. Liver Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2147\/CLEP.S403314","article-title":"Association between serum uric acid and non-alcoholic fatty liver disease: An updated systematic review and meta-analysis","volume":"15","author":"Sun","year":"2023","journal-title":"Clin. Epidemiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/hepr.12656","article-title":"The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment","volume":"46","author":"Ballestri","year":"2016","journal-title":"Hepatol. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/j.jhep.2023.12.009","article-title":"Uric acid may serve as the sixth cardiometabolic criterion for defining MASLD","volume":"80","author":"He","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e240186","DOI":"10.1530\/EC-24-0186","article-title":"Nomogram for predicting 5-year metabolic dysfunction-associated steatotic liver disease risk: Retrospective cohort study","volume":"13","author":"Gao","year":"2024","journal-title":"Endocr. Connect."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Al-Shargi, A., El Kholy, A.A., Adel, A., Hassany, M., and Shaheen, S.M. (2023). Allopurinol versus Febuxostat: A new approach for the management of hepatic steatosis in metabolic dysfunction-associated steatotic liver disease. Biomedicines, 11.","DOI":"10.3390\/biomedicines11113074"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"He, R., Gao, S., Yao, H., Zhao, Z., Tong, J., and Zhang, H. (2023). Mechanism of metabolic response to hepatectomy by integrated analysis of gut microbiota, metabolomics, and proteomics. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.02067-22"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.clinbiochem.2016.05.016","article-title":"Serum metabolomics of NAFLD plus T2DM based on liquid chromatography-mass spectrometry","volume":"49","author":"Chen","year":"2016","journal-title":"Clin. Biochem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1080\/00365521.2023.2225667","article-title":"Mass spectrometry-based untargeted metabolomics study of non-obese individuals with non-alcoholic fatty liver disease","volume":"58","author":"Demirel","year":"2023","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_54","unstructured":"National Library of Medicine (2024, June 24). PubChem Compound, Available online: https:\/\/www.ncbi.nlm.nih.gov\/pccompound\/."},{"key":"ref_55","first-page":"3","article-title":"Precision medicine approaches in metabolic disorders and target organ damage: Where are we now, and where are we going?","volume":"1","author":"Lonardo","year":"2021","journal-title":"Metab. Target. Organ. Damage"}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/14\/8\/408\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:24:22Z","timestamp":1760109862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/14\/8\/408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":55,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["metabo14080408"],"URL":"https:\/\/doi.org\/10.3390\/metabo14080408","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]}}}